Abstract
DNA methylation (DNAm) age acceleration, defined as the deviation of chronological and epigenetic age determined by an epigenetic clock, has been proposed as a biomarker of biological aging. To address the above hypothesis in the context of cardiovascular disease, we evaluated whether patients (N=827, mean chronological age: 69.82±11.01 years, DNAm age: 71.91±16.11, residual DNAm age acceleration: 0.00±9.65 years), who were diagnosed with obstructive coronary artery disease (CAD) by coronary angiography were aged prematurely, i.e. had an increase in the DNAm age acceleration, in comparison with patients for whom obstructive CAD was ruled out (controls).
Stratified analysis yielded a significant acceleration in DNAm age (determined by a seven cytosine-phosphate-guanine epigenetic clock) in patients diagnosed with obstructive CAD, defined by at least one >50% coronary stenosis (N=588, rDNA age acceleration=0.58±9.47, corrected p= 2.05⨯10−3) compared to control subjects (N=145, residual (r)DNAm age acceleration= -3.11±10.51 years). Moreover, rDNAm age acceleration was significantly associated with systolic blood pressure (ß=0.069, 95% CI 0.027 – 0.112, p= 1.44⨯10−3), sex (ß=-2.438, 95% CI -4.591 - -0.285, p= 2.65⨯10−2), estimated glomerular filtration rate (eGFR, ß=0.040, 95% CI 0.011 – 0.069, p= 6.87⨯10−9) and smoking status (ß=-8.538, 95% CI -10.772 - -6.303, p= 2,45⨯10−13).
Across studies, assessing CAD and its risk factors in the context of epigenetic age acceleration findings are remarkably inconclusive. While the here employed seven-cytosine-phosphate-guanine epigenetic clock suggests premature biological aging in CAD patients, compared to controls without coronary stenosis, its association with cardiovascular risk factors was limited.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The LipidCardio study was partly funded by the Sanofi-Aventis Deutschland GmbH. The provided support was exclusively financial, with no influence on study design, data collection and analysis, nor the decision to publish, nor the preparation of this manuscript. The BASE-II research project (Principle-Investigators: Lars Bertram, Ilja Demuth, Denis Gerstorf, Ulman Lindenberger, Graham Pawelec, Elisabeth Steinhagen-Thiessen, and Gert G. Wagner) was supported by the German Federal Ministry of Education and Research (Bundesministerium für Bildung und Forschung, BMBF) under grant numbers: #16SV5536K, #16SV5537, #16SV5538, #16SV5837, #01UW0808, 01GL1716A and 01GL1716B. The provided support was exclusively financial, with no influence on study design, data collection and analysis, nor the decision to publish, nor the preparation of this manuscript. Additional funding was provided by the Max Planck Institute for Human Development, Berlin, Germany. Contributions (e.g., equipment, logistics, personnel) were made from each of the other participating sites.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Due to concerns for participant privacy, data are available only upon request. External scientists may apply to the Steering Committee of LipidCardio for data access. Please contact the study coordinating PI Ilja Demuth at ilja.demuth@charite.
